These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10971827)

  • 1. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy.
    Heijtink RA; Janssen HL; Hop WC; Osterhaus AD; Schalm SW
    J Viral Hepat; 2000 Sep; 7(5):382-6. PubMed ID: 10971827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
    van der Eijk AA; Niesters HG; Hansen BE; Heijtink RA; Janssen HL; Schalm SW; de Man RA
    J Viral Hepat; 2006 Feb; 13(2):96-103. PubMed ID: 16436127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Janssen HL; Gerken G; Carreño V; Marcellin P; Naoumov NV; Craxi A; Ring-Larsen H; Kitis G; van Hattum J; de Vries RA; Michielsen PP; ten Kate FJ; Hop WC; Heijtink RA; Honkoop P; Schalm SW
    Hepatology; 1999 Jul; 30(1):238-43. PubMed ID: 10385662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
    J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
    Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
    Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
    Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
    Luo XD; Chen XP; Chen XF
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
    [No Abstract]   [Full Text] [Related]  

  • 15. [Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a].
    Li MH; Xie Y; Wu YZ; Xu DZ; Lu ZM; Hou JL; Jia JD; Wang YM; Zhang SL; Ren H; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jul; 15(7):481-4. PubMed ID: 17669233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].
    Luo XD; Chen XP; Chen XF
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):583-588. PubMed ID: 29056007
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B.
    Heijtink RA; Kruining J; Honkoop P; Kuhns MC; Hop WC; Osterhaus AD; Schalm SW
    J Med Virol; 1997 Nov; 53(3):282-7. PubMed ID: 9365897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.